Beclazon Eco, aerosol 50 mcg/dose 200 doses

HKS for inhalation use. It has anti-inflammatory and anti-allergic effects.

Inhibits release of inflammatory mediators, increases production of lipomodulin – phospholipase A inhibitor, decreases release of arachidonic acid, inhibits synthesis of prostaglandins. It prevents marginal accumulation of neutrophils by reducing inflammatory exudate formation and lymphokine production, inhibits macrophage migration, which leads to slowdown of infiltration and granulation processes.

It increases the number of active β-adrenoreceptors, neutralizes their desensitization, restores the patient’s response to bronchodilators, allowing us to reduce the frequency of their use.

Beclomethasone decreases the number of mast cells in the bronchial mucosa, reduces swelling of the epithelium and mucus secretion by the bronchial glands. Causes relaxation of the smooth muscles of the bronchi, reduces their hyperresponsiveness and improves the indices of external respiratory function.

Does not have mineralocorticoid activity.

In therapeutic doses, it does not cause side effects typical for systemic GCS.

In intranasal administration, it eliminates edema and hyperemia of the nasal mucosa.

Therapeutic effect usually develops after 5-7 days of course use of beclomethasone.

When used topically or topically, it has anti-allergic and anti-inflammatory effects.

Indications

For inhaled use: treatment of bronchial asthma (including when bronchodilators and/or sodium cromoglycate are not effective, as well as hormone-dependent bronchial asthma of severe course in adults and children).

For intranasal use: prevention and treatment of year-round and seasonal allergic rhinitis, including rhinitis in hay fever, vasomotor rhinitis.

For topical and external use: in combination with antimicrobials for infectious inflammatory skin and ear conditions.

Active ingredient

Composition

1 dose of the aerosol contains:

Ethanol, hydrofluoroalkane (HFA-134a).

How to take, the dosage

Beclazon Echo is intended for inhalation administration only.

Beclazon Echo is used regularly (even in the absence of symptoms), the dose of beclomethasone dipropionate is adjusted according to the clinical effect in each case:

When switching to high-dose inhaled beclomethasone dipropionate, many patients who receive systemic glucocorticosteroids can reduce their dose or discontinue them altogether.

The starting dose of Beclazon Echo is determined by the severity of bronchial asthma.

The daily dose is divided into several doses. Depending on the individual response of the patient, the dose of the drug may be increased until clinical effect is seen or decreased to the minimum 1 effective dose.

Adults and children 12 years of age and older:

The treatment of bronchial asthma is based on a step-by-step approach – therapy is started according to the stage corresponding to the severity of the disease.

Inhaled GCSs are prescribed in the second step of therapy.

Beclomethasone dipropionate 100-400 mcg 2 times a day.

Inhaled GKS are used in a high dose or in a standard dose, but in combination with long-acting inhaled beta-2-adrenoreceptor antagonists. Beclomethasone dipropionate in high dose – 800-1600 mcg/day, in some cases mega doses up to 2000 mcg/day.

Beclomethasone dipropionate in high doses of 800-1600 mcg/day, in some cases mega doses up to 2000 mcg/day.

Beclomethasone dipropionate in high dose (see step 3,4).

Children 4 to 12 years of age up to 400 mcg per day in multiple doses.

There is no need to adjust the dose of Beclazon Echo in the elderly, in patients with renal or hepatic impairment.

If you accidentally miss an inhalation, the next dose must be taken at the correct time according to the treatment regimen.

Interaction

Concomitant use of beclomethasone with other GCSs for systemic or intranasal use may increase suppression of adrenal cortical function. Prior inhaled use of beta-adrenergic stimulants may increase the clinical efficacy of beclomethasone.

Special Instructions

Beclomethasone is not intended to relieve acute asthma attacks. It should also not be used in severe attacks of bronchial asthma requiring intensive therapy. The recommended route of administration for the dosage form used should be strictly observed.

Beclomethasone should be used with extreme caution and under close medical supervision in patients with adrenal insufficiency.

Transfer patients who are always taking oral GCS to inhaled forms should only be done when they are stable.

If paradoxical bronchospasm is likely to develop, bronchodilators (e.g., salbutamol) should be inhaled 10-15 minutes before inhaling beclomethasone.

If candidiasis of the oral cavity and upper respiratory tract develops, local antifungal therapy is indicated without stopping treatment with beclomethasone. Infectious inflammatory diseases of the nasal cavity and sinuses are not contraindications to beclomethasone therapy when therapy is indicated.

Inhaled preparations containing 250 mcg beclometasone in 1 dose are not indicated for children under 12 years of age.

Contraindications

Hypersensitivity to the ingredients of the drug.

With caution:

-glaucoma;

-systemic infections (bacterial, viral, fungal, parasitic);

-osteoporosis;

-tuberculosis of the lungs;

-hypothyroidism;

-pregnancy;

-lactation period.

Side effects

Respiratory system: hoarseness, sensation of irritation in the throat, sneezing; rarely – cough; in single cases – eosinophilic pneumonia, paradoxical bronchospasm, with intranasal use – nasal septum perforation. Candidiasis of the oral cavity and upper respiratory tract, especially with long-term use, is possible, passing with local antifungal therapy without stopping treatment.

Allergic reactions: rash, urticaria, pruritus, erythema and swelling of the eyes, face, lips and throat.

Systemic effects: decreased adrenal cortical function, osteoporosis, cataracts, glaucoma, growth retardation in children.

Overdose

Acute overdose

Chronic overdose

In case of overdose, treatment with beclomethasone dipropionate may be continued in doses sufficient to maintain the therapeutic effect.

Pregnancy use

It is contraindicated in the first trimester of pregnancy.

The use in the second and third trimesters of pregnancy is possible only when the estimated benefit to the mother exceeds the potential risk to the fetus. Newborns whose mothers received beclomethasone during pregnancy should be carefully evaluated for adrenal insufficiency.

If use during lactation is necessary, discontinuation of breastfeeding should be considered.

Similarities